CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023

Company Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.

It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.

It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta.

The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014.

CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTI BioPharma Corp.
CTI BioPharma logo
Country United States
Founded 1991
IPO Date Mar 21, 1997
Industry Biotechnology
Sector Healthcare
Employees 127
CEO Dr. Adam R. Craig M.B.A., M.D., Ph.D.

Contact Details

Address:
3101 Western Avenue, Suite 800
Seattle, Washington 98121
Phone (206) 282-7100
Website ctibiopharma.com

Stock Details

Ticker Symbol CTIC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000891293
CUSIP Number 12648L601
ISIN Number US12648L6011
Employer ID 91-1533912
SIC Code 2834

Key Executives

Name Position
Dr. Adam R. Craig M.B.A., M.D., Ph.D. President, Chief Executive Officer, Interim Chief Medical Officer and Director
David H. Kirske Executive Vice President, Chief Financial Officer and Secretary
Ed Bell Senior Director of Investor Relations
James K. Fong Executive Vice President and Chief Commercial Officer
Bruce K. Bennett Jr. Senior Vice President Global Pharmaceutical Operations
John P. Volpone Executive Vice President and Chief of Staff
Dr. Jennifer A. Smith Senior Vice President of Biometrics

Latest SEC Filings

Date Type Title
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 POS AM Post-Effective amendments for registration statement
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jun 26, 2023 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments